Cargando…
Antiseizure and Neuroprotective Efficacy of Midazolam in Comparison with Tezampanel (LY293558) against Soman-Induced Status Epilepticus
Acute exposure to nerve agents induces status epilepticus (SE), which can cause death or long-term brain damage. Diazepam is approved by the FDA for the treatment of nerve agent-induced SE, and midazolam (MDZ) is currently under consideration to replace diazepam. However, animal studies have raised...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330837/ https://www.ncbi.nlm.nih.gov/pubmed/35893842 http://dx.doi.org/10.3390/toxics10080409 |
_version_ | 1784758258823593984 |
---|---|
author | Figueiredo, Taiza H. Aroniadou-Anderjaska, Vassiliki Pidoplichko, Volodymyr I. Apland, James P. Braga, Maria F. M. |
author_facet | Figueiredo, Taiza H. Aroniadou-Anderjaska, Vassiliki Pidoplichko, Volodymyr I. Apland, James P. Braga, Maria F. M. |
author_sort | Figueiredo, Taiza H. |
collection | PubMed |
description | Acute exposure to nerve agents induces status epilepticus (SE), which can cause death or long-term brain damage. Diazepam is approved by the FDA for the treatment of nerve agent-induced SE, and midazolam (MDZ) is currently under consideration to replace diazepam. However, animal studies have raised questions about the neuroprotective efficacy of benzodiazepines. Here, we compared the antiseizure and neuroprotective efficacy of MDZ (5 mg/kg) with that of tezampanel (LY293558; 10 mg/kg), an AMPA/GluK1 receptor antagonist, administered 1 h after injection of the nerve agent, soman (1.2 × LD(50)), in adult male rats. Both of the anticonvulsants promptly stopped SE, with MDZ having a more rapid effect. However, SE reoccurred to a greater extent in the MDZ-treated group, resulting in a significantly longer total duration of SE within 24 h post-exposure compared with the LY293558-treated group. The neuroprotective efficacy of the two drugs was studied in the basolateral amygdala, 30 days post-exposure. Significant neuronal and inter-neuronal loss, reduced ratio of interneurons to the total number of neurons, and reduction in spontaneous inhibitory postsynaptic currents accompanied by increased anxiety were found in the MDZ-treated group. The rats treated with LY293558 did not differ from the control rats (not exposed to soman) in any of these measurements. Thus, LY293558 has significantly greater efficacy than midazolam in protecting against prolonged seizures and brain damage caused by acute nerve agent exposure. |
format | Online Article Text |
id | pubmed-9330837 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93308372022-07-29 Antiseizure and Neuroprotective Efficacy of Midazolam in Comparison with Tezampanel (LY293558) against Soman-Induced Status Epilepticus Figueiredo, Taiza H. Aroniadou-Anderjaska, Vassiliki Pidoplichko, Volodymyr I. Apland, James P. Braga, Maria F. M. Toxics Article Acute exposure to nerve agents induces status epilepticus (SE), which can cause death or long-term brain damage. Diazepam is approved by the FDA for the treatment of nerve agent-induced SE, and midazolam (MDZ) is currently under consideration to replace diazepam. However, animal studies have raised questions about the neuroprotective efficacy of benzodiazepines. Here, we compared the antiseizure and neuroprotective efficacy of MDZ (5 mg/kg) with that of tezampanel (LY293558; 10 mg/kg), an AMPA/GluK1 receptor antagonist, administered 1 h after injection of the nerve agent, soman (1.2 × LD(50)), in adult male rats. Both of the anticonvulsants promptly stopped SE, with MDZ having a more rapid effect. However, SE reoccurred to a greater extent in the MDZ-treated group, resulting in a significantly longer total duration of SE within 24 h post-exposure compared with the LY293558-treated group. The neuroprotective efficacy of the two drugs was studied in the basolateral amygdala, 30 days post-exposure. Significant neuronal and inter-neuronal loss, reduced ratio of interneurons to the total number of neurons, and reduction in spontaneous inhibitory postsynaptic currents accompanied by increased anxiety were found in the MDZ-treated group. The rats treated with LY293558 did not differ from the control rats (not exposed to soman) in any of these measurements. Thus, LY293558 has significantly greater efficacy than midazolam in protecting against prolonged seizures and brain damage caused by acute nerve agent exposure. MDPI 2022-07-22 /pmc/articles/PMC9330837/ /pubmed/35893842 http://dx.doi.org/10.3390/toxics10080409 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Figueiredo, Taiza H. Aroniadou-Anderjaska, Vassiliki Pidoplichko, Volodymyr I. Apland, James P. Braga, Maria F. M. Antiseizure and Neuroprotective Efficacy of Midazolam in Comparison with Tezampanel (LY293558) against Soman-Induced Status Epilepticus |
title | Antiseizure and Neuroprotective Efficacy of Midazolam in Comparison with Tezampanel (LY293558) against Soman-Induced Status Epilepticus |
title_full | Antiseizure and Neuroprotective Efficacy of Midazolam in Comparison with Tezampanel (LY293558) against Soman-Induced Status Epilepticus |
title_fullStr | Antiseizure and Neuroprotective Efficacy of Midazolam in Comparison with Tezampanel (LY293558) against Soman-Induced Status Epilepticus |
title_full_unstemmed | Antiseizure and Neuroprotective Efficacy of Midazolam in Comparison with Tezampanel (LY293558) against Soman-Induced Status Epilepticus |
title_short | Antiseizure and Neuroprotective Efficacy of Midazolam in Comparison with Tezampanel (LY293558) against Soman-Induced Status Epilepticus |
title_sort | antiseizure and neuroprotective efficacy of midazolam in comparison with tezampanel (ly293558) against soman-induced status epilepticus |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330837/ https://www.ncbi.nlm.nih.gov/pubmed/35893842 http://dx.doi.org/10.3390/toxics10080409 |
work_keys_str_mv | AT figueiredotaizah antiseizureandneuroprotectiveefficacyofmidazolamincomparisonwithtezampanelly293558againstsomaninducedstatusepilepticus AT aroniadouanderjaskavassiliki antiseizureandneuroprotectiveefficacyofmidazolamincomparisonwithtezampanelly293558againstsomaninducedstatusepilepticus AT pidoplichkovolodymyri antiseizureandneuroprotectiveefficacyofmidazolamincomparisonwithtezampanelly293558againstsomaninducedstatusepilepticus AT aplandjamesp antiseizureandneuroprotectiveefficacyofmidazolamincomparisonwithtezampanelly293558againstsomaninducedstatusepilepticus AT bragamariafm antiseizureandneuroprotectiveefficacyofmidazolamincomparisonwithtezampanelly293558againstsomaninducedstatusepilepticus |